## Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

GALECTIN Form 4 January 02, 2	THERAPEUTIC	S INC	3	-		-						
									OMB A	PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287				
Check the if no long							Expires:	January 31, 2005				
subject to Section 1 Form 4 o	F CHANGES IN BENEFICIAL OWNERSHIP O SECURITIES						Estimated a burden hou	average Irs per				
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations May continue. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										0.5		
(Print or Type I	Responses)											
1. Name and Address of Reporting Person <u>*</u> MAULDIN JOHN F			2. Issuer Name <b>and</b> Ticker or Trading Symbol				ıg	5. Relationship of Reporting Person(s) to Issuer				
			GALECTIN THERAPEUTICS INC [GALT]					(Check all applicable)				
				3. Date of Earliest Transaction				X_ Director 10% Owner Officer (give title Other (specify				
INC., 4960	CTIN THERAPE PEACHTREE AL BLVD, STE 2		(Month/D 01/02/20	-				below)	below)	er (speeny		
					mendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line)			
NORCROSS, GA 30071				F					_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table	e I - Non-D	erivative	Securi	ities Acc	quired, Disposed o	f, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Dee Execution any (Month/Day/Year)				4. Securi on(A) or Di (D) (Instr. 3,	ispose	d of	Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
				Code V	Amount	or	Price	Transaction(s) (Instr. 3 and 4)				
Common Stock	01/02/2014			P <u>(1)</u>	618	А	\$ 8.01	18,074	D			
Common Stock								4,947	Ι	By Trust		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address			Relationships						
		Director	10% Owner	Officer	Other				
MAULDIN JOHN F C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD NORCROSS, GA 30071	, STE 240	X							
Signatures									
/s/ Jack W. Callicutt, Attorney-in-Fact	01/02/2014								
**Signature of Reporting Person	Date								

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.